CLiRpath Featured on Discovery Health Channel's 'Medical Incredible'

CLiRpath Featured on Discovery Health Channel's 'Medical Incredible'

COLORADO SPRINGS, Colo., June 8 /PRNewswire-FirstCall/ -- Spectranetics Corporation's (NASDAQ:SPNC) CLiRpath(R) cool laser technology was featured on Discovery Health Channel's "Medical Incredible" program on June 5.

Dr. Daniel Garnic, an interventional radiologist at Glendale Memorial Hospital in Los Angeles, Calif., performed the CLiRpath procedure on the segment featuring a patient suffering from Critical Limb Ischemia. The segment exhibited the patient's transformation from barely being able to walk to relatively pain-free mobilization following the procedure.

"The word is getting out about this extraordinary treatment," said Dr. Garnic. "There has been a great response since the program aired confirming the need for this technology today and into the future."

Discovery Health is a cable channel offering programming about medical breakthroughs, healthy stories and the ever changing world of healthcare. The CLiRpath segment on "Medical Incredible", entitled "Reconstructed Brain", will air again on the following dates:

* June 11 at 5 p.m., Mountain Daylight Time (7 p.m. Eastern Daylight Time)
* June 12 at 12 a.m., Mountain Daylight Time (2 a.m. Eastern Daylight
Time)

About Spectranetics

Spectranetics is a medical device company that develops, manufactures and markets single-use medical devices used in minimally invasive surgical procedures within the cardiovascular system in conjunction with its proprietary excimer laser system. Excimer laser technology delivers relatively cool ultraviolet energy to ablate or remove arterial blockages including plaque, calcium and thrombus. We believe our CVX-300(R) excimer laser is the only system approved in the United States, Europe, Japan, and Canada for use in multiple, minimally invasive cardiovascular procedures. These procedures include atherectomy, which is a procedure to remove arterial blockages in the peripheral or coronary vasculature, and the removal of infected, defective or abandoned cardiac lead wires from patients with pacemakers or implantable cardiac defibrillators, or ICDs, which are electronic devices that regulate the heartbeat.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties may include increasing price and product competition, increased pressure on expense levels resulting from expanded marketing and clinical activities, uncertain success of the Company's strategic direction, dependence on new product development, intellectual property claims of third parties, availability of inventory from suppliers, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, the potential size of market opportunities associated with new products, market acceptance of new products or applications, product defects, price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from any anticipated results, performance or achievements, please see the Company's previously filed SEC reports. Spectranetics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise.

Spectranetics and CVX-300 are registered trademarks of The Spectranetics Corporation.

COMPANY CONTACT:
Spectranetics Corporation
Guy Childs, Chief Financial Officer
(719) 633-8333
www.spectranetics.com

INVESTOR & MEDIA CONTACTS:
Lippert/Heilshorn & Associates, Inc.
Bruce Voss
Don Markley
(310) 691-7100
www.lhai.com

Source: Spectranetics Corporation

CONTACT: Guy Childs, Chief Financial Officer of Spectranetics
Corporation, +1-719-633-8333; or Investors & Media, Bruce Voss or Don Markley,
both of Lippert/Heilshorn & Associates, Inc., +1-310-691-7100, for
Spectranetics Corporation

Web site: http://www.spectranetics.com/
http://www.lhai.com/

-------
Profile: intent